Actively Recruiting
Italian Tumor Chemogenomic Profiler IT-TCP An Integrative Multi-Omics and Functional Platform for Complete Diagnostic Characterization of High-Risk Tumors
Led by Azienda Ospedaliero-Universitaria di Parma · Updated on 2026-02-17
300
Participants Needed
2
Research Sites
53 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying primary samples from patients diagnosed with high-risk hematological or solid tumors, including metastatic, recurrent, or refractory cases. This experimental preclinical study aims to better understand these tumors using advanced diagnostic approaches. The study is prospective, enrolling patients consecutively at multiple institutions based on their clinical and biological characteristics at diagnosis. The study involves functional tests where malignant cells from patient samples are exposed to a library of 300 drugs at different concentrations for 72 hours. In addition, multi-omics analyses such as radiomics, digital pathology, immune profiling, transcriptomics, phosphoproteomics, and genetic studies including cytogenetics and FISH will be conducted. These combined methods form an integrative platform for detailed tumor characterization. Participants will provide primary tumor samples that undergo various laboratory analyses to evaluate potential changes in therapeutic indications compared to standard care. Data management and storage will be supported by a dedicated IT platform. The main outcome measure is the rate of change in therapeutic recommendations at baseline. The study includes ongoing monitoring of clinical and biological data, aiming to inform future treatment strategies for high-risk tumors.
CONDITIONS
Brief Title
INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
Research Team
G
Giovanni Roti, Associate Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here